Molecular therapies and precision medicine for hepatocellular carcinoma
Top Cited Papers
Open Access
- 30 July 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 15 (10), 599-616
- https://doi.org/10.1038/s41571-018-0073-4
Abstract
The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass an annual incidence of 1 million cases. Genomic studies have established the landscape of molecular alterations in HCC; however, the most common mutations are not actionable, and only ~25% of tumours harbour potentially targetable drivers. Despite the fact that surveillance programmes lead to early diagnosis in 40–50% of patients, at a point when potentially curative treatments are applicable, almost half of all patients with HCC ultimately receive systemic therapies. Sorafenib was the first systemic therapy approved for patients with advanced-stage HCC, after a landmark study revealed an improvement in median overall survival from 8 to 11 months. New drugs — lenvatinib in the frontline and regorafenib, cabozantinib, and ramucirumab in the second line — have also been demonstrated to improve clinical outcomes, although the median overall survival remains ~1 year; thus, therapeutic breakthroughs are still needed. Immune-checkpoint inhibitors are now being incorporated into the HCC treatment armamentarium and combinations of molecularly targeted therapies with immunotherapies are emerging as tools to boost the immune response. Research on biomarkers of a response or primary resistance to immunotherapies is also advancing. Herein, we summarize the molecular targets and therapies for the management of HCC and discuss the advancements expected in the near future, including biomarker-driven treatments and immunotherapies.This publication has 138 references indexed in Scilit:
- MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517aGastroenterology, 2011
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic ScreeningCancer Cell, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 ActivationOnline Journal of Public Health Informatics, 2010
- Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent AdvancementsSeminars in Liver Disease, 2010
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalJournal of Hepatology, 2003
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002